Citation Impact
Citing Papers
HER-2 Gene Amplification, HER-2 and Epidermal Growth Factor Receptor mRNA and Protein Expression, and Lapatinib Efficacy in Women with Metastatic Breast Cancer
2008
Tissue microarray technology in breast cancer HER2 diagnostics
2007
External Quality Assurance of HER2 FISH and ISH Testing
2008
Reliability of Human Epidermal Growth Factor Receptor 2 Immunohistochemistry in Breast Core Needle Biopsies
2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
2010 Standout
Hallmarks of Cancer: The Next Generation
2011 Standout
Comparative analysis of six different antibodies against Her2 including the novel rabbit monoclonal antibody (SP3) and chromogenic in situ hybridisation in breast carcinomas
2008
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
2013 Standout
Incorporating gold nanoclusters and target-directed liposomes as a synergistic amplified colorimetric sensor for HER2-positive breast cancer cell detection
2017
A UK NEQAS ISH Multicenter Ring Study Using the Ventana HER2 Dual-Color ISH Assay
2010
Biologic and therapeutic role of HER2 in cancer
2003
Rabbit antibodies for hormone receptors and HER2 evaluation in breast cancer
2009
Comparison of quantitative immunofluorescence with conventional methods for HER2/neu testing with respect to response to trastuzumab therapy in metastatic breast cancer.
2008
Hypoxia-Inducible Factor Linked to Differential Kidney Cancer Risk Seen with Type 2A and Type 2B VHL Mutations
2007 StandoutNobel
Comparison of Quantitative Immunofluorescence With Conventional Methods for HER2/ neu Testing With Respect to Response to Trastuzumab Therapy in Metastatic Breast Cancer
2008
PGDS, A Novel Technique Combining Chromogenic In Situ Hybridization and Immunohistochemistry for the Assessment of ErbB2 (HER2/neu) Status in Breast Cancer
2007
A view on drug resistance in cancer
2019 StandoutNature
Prediction of HER2 gene status in Her2 2+ invasive breast cancer: a study of 108 cases comparing ASCO/CAP and FDA recommendations
2008
Right Hepatectomy for Living Liver Donation vs Right Hepatectomy for Disease
2007
Cell production rates in human tissues and tumours and their significance. Part II: clinical data
2000
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention
2011 Standout
How Tumors Become Angiogenic
1996
Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis
1996 Standout
Determination ofHER2Amplification by In Situ Hybridization
2008
Molecular basis of the VHL hereditary cancer syndrome
2002 StandoutNobel
Imaging in the era of molecular oncology
2008 StandoutNature
Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma
1996
Head and neck cancer
2008 Standout
Heparin-Induced Thrombocytopenia
1998
Distant metastasis occurs late during the genetic evolution of pancreatic cancer
2010 StandoutNature
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
2006 Standout
Vascular Endothelial Growth Factor Regulates Endothelial Cell Survival through the Phosphatidylinositol 3′-Kinase/Akt Signal Transduction Pathway
1998 Standout
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
2004 Standout
Angiogenesis in cancer and other diseases
2000 StandoutNature
The Hallmarks of Cancer
2000 Standout
Photodynamic therapy for cancer
2003 Standout
A UK NEQAS ICC and ISH multicentre study using the Kreatech Poseidon HER2 FISH probe: intersite variation can be rigorously controlled using FISH
2010
Chromogenic in situ hybridisation (CISH) should be an accepted method in the routine diagnostic evaluation of HER2 status in breast cancer
2007
Determination of HER2 Gene Amplification by Fluorescence In situ Hybridization and Concordance with the Clinical Trials Immunohistochemical Assay in Women with Metastatic Breast Cancer Evaluated for Treatment with Trastuzumab
2005
Bright-field In Situ Hybridization for HER2 Gene Amplification in Breast Cancer Using Tissue Microarrays
2009
Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs
2003
Assessing responses to cancer therapy using molecular imaging
2006
Epithelial–mesenchymal transitions in tumour progression
2002 Standout
Estimates of Early Death, Acute Liver Failure, and Long-term Mortality Among Live Liver Donors
2011
The Sentinel Node in Breast Cancer — A Multicenter Validation Study
1998 Standout
Impact of Clinical and Non-Clinical Factors on the Choice of HER2 Test for Breast Cancer
2010
Determinants and clinical implications of chromosomal instability in cancer
2018
Male breast cancer
2006 Standout
A public-domain image processing tool for automated quantification of fluorescence in situ hybridisation signals
2007
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
2007 Standout
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
2011 Standout
Coupling of angiogenesis and osteogenesis by a specific vessel subtype in bone
2014 StandoutNature
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
2004 Standout
<i>HER2</i> Evaluation and Its Impact on Breast Cancer Treatment Decisions
2011
ClustVis: a web tool for visualizing clustering of multivariate data using Principal Component Analysis and heatmap
2015 Standout
Repertoires of Autophagy in the Pathogenesis of Ocular Diseases
2015 Standout
Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs
2001
Sentinel lymphadenectomy in breast cancer.
1997
Imaging of angiogenesis: from microscope to clinic
2003
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
2011 Standout
Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1α
1998 StandoutNobel
Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein
2002 StandoutNobel
Donor Outcome After Living Liver Donation: A Single-Center Experience
2007
Nanoparticle and targeted systems for cancer therapy
2004 Standout
Global challenges in liver disease
2006
Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin Signaling
2009 Standout
The Clavien-Dindo Classification of Surgical Complications
2009 Standout
Synthesis of Heterobifunctional Protein Fusions Using Copper‐Free Click Chemistry and the Aldehyde Tag
2012 StandoutNobel
Molecular Regulation of Vascular Smooth Muscle Cell Differentiation in Development and Disease
2004 Standout
Epidermal growth factor receptor expression in primary laryngeal cancer: An independent prognostic factor of neck node relapse
1999
Replication of hepatitis C virus
2007 StandoutNobel
Fifteen-year prognostic discriminants for invasive breast carcinoma
2001
Iron Catalysis in Organic Synthesis
2015 Standout
Upconversion Nanoparticles: Design, Nanochemistry, and Applications in Theranostics
2014 Standout
Tyrosine Kinase Inhibitors. 10. Isomeric 4-[(3-Bromophenyl)amino]pyrido[d]- pyrimidines Are Potent ATP Binding Site Inhibitors of the Tyrosine Kinase Function of the Epidermal Growth Factor Receptor
1996
Evaluation of HER2/neu gene amplification in patients with invasive breast carcinoma. Comparison of in situ hybridization methods.
2007
Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: Induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal
1997
HER2 Testing in Breast Cancer: NCCN Task Force Report and Recommendations
2006
Vascular Targeting Agents as Cancer Therapeutics
2004
Human Epidermal Growth Factor Receptor 2 Status Correlates With Lymph Node Involvement in Patients With Estrogen Receptor (ER) –Negative, but With Grade in Those With ER-Positive Early-Stage Breast Cancer Suitable for Cytotoxic Chemotherapy
2007
Development of meta-tetrahydroxyphenylchlorin-monoclonal antibody conjugates for photoimmunotherapy.
1999
Redefining the Target: Chemotherapeutics as Antiangiogenics
2001
Effect of epidermal growth factor receptor tyrosine kinase inhibition on epithelial proliferation in normal and premalignant breast.
2002
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Estrogen and Angiogenesis
2001
Tyrosine Kinase Inhibitors. 13. Structure−Activity Relationships for Soluble 7-Substituted 4-[(3-Bromophenyl)amino]pyrido[4,3-d]pyrimidines Designed as Inhibitors of the Tyrosine Kinase Activity of the Epidermal Growth Factor Receptor
1997
2000 Update of Recommendations for the Use of Tumor Markers in Breast and Colorectal Cancer: Clinical Practice Guidelines of the American Society of Clinical Oncology*
2001
Pigment Epithelium-Derived Factor: A Potent Inhibitor of Angiogenesis
1999 StandoutScience
Nanomaterials with enzyme-like characteristics (nanozymes): next-generation artificial enzymes (II)
2018 Standout
A Pictet-Spengler ligation for protein chemical modification
2012 StandoutNobel
Current trends in live liver donation
2006
Response of Hepatitis C Virus to Long-Term Passage in the Presence of Alpha Interferon: Multiple Mutations and a Common Phenotype
2013 StandoutNobel
Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis
2017 Standout
Risk of End-Stage Renal Disease Following Live Kidney Donation
2014 Standout
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
2005 StandoutScience
Advances in Copper Complexes as Anticancer Agents
2013 Standout
Angiogenesis in Endocrine Tumors
2003
Tissue- and Organ-Selective Biodistribution of NIR Fluorescent Quantum Dots
2009 StandoutNobel
Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies.
2000
Role ofVHLGene Mutation in Human Cancer
2004 StandoutNobel
Evaluation of Lymph Node Status in Male Breast Cancer Patients: A Role for Sentinel Lymph Node Biopsy*
2003
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials
2005 Standout
Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy
1999 StandoutNobel
Works of Peter Stanton being referenced
Outcome and Human Epithelial Growth Factor Receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated using bromodeoxyuridine (BrdU) labelling
2004
The value of the human epidermal growth factor receptor-2 (HER2) as a prognostic marker
2001
Quantitative estimation of epidermal growth factor receptor and c-erbB-2 in human breast cancer.
1996
Radioimmunohistochemistry of Epidermal Growth Factor Receptor in Breast Cancer
2002
HER2 as a prognostic and predictive marker for breast cancer
2001
Epidermal growth factor receptor expression by human squamous cell carcinomas of the head and neck, cell lines and xenografts
1994
Oestrogen receptor status predicts local recurrence following breast conservation surgery for early breast cancer
1998
Prognostic value of ploidy of primary tumour and nodal secondaries in colorectal cancers
1994
Evaluating HER2 amplification and overexpression in breast cancer
2001
Living donor liver transplantation—Adult donor outcomes: A systematic review
2005
Relationship of endothelial cell proliferation to tumor vascularity in human breast cancer.
1993
Sentinel node localization in patients with breast cancer
1998
Heparin-associated skin necrosis
1990
Cell kinetics in vivo of human breast cancer
1996